Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01093 CSPC PHARMA
RTNominal up6.600 +0.080 (+1.227%)
Research Report

31/03/2020 17:30

{I-bank focus}CLSA trims CSPC Pharma (01093) to HK$22.34

[ET Net News Agency, 31 March 2020] CLSA cut its target price for CSPC Pharmaceutical
Group (01093) to HK$22.34 from HK$23.37 considering the ongoing outbreak and slight miss
in the 2019 results. CLSA maintained its "buy" rating.
The research house said CSPC's 2019 attributable net profit of Rmb3,714m (up 20.6%)
missed CLSA's profit growth forecast of 24.1%. It believes the company would still succeed
due to its strong promotion network and rapid growth in oncology drugs. (KL)

Back to Research Report

Remark: Real time quote last updated: 26/04/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.